Short Interest in Liminatus Pharma Inc. (NASDAQ:LIMN) Decreases By 51.2%

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a significant decrease in short interest during the month of February. As of February 27th, there was short interest totaling 1,307,493 shares, a decrease of 51.2% from the February 12th total of 2,677,258 shares. Based on an average daily volume of 7,073,285 shares, the short-interest ratio is presently 0.2 days. Approximately 4.2% of the company’s shares are sold short. Approximately 4.2% of the company’s shares are sold short. Based on an average daily volume of 7,073,285 shares, the short-interest ratio is presently 0.2 days.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Monday, December 29th. Wall Street Zen cut Liminatus Pharma from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Liminatus Pharma currently has a consensus rating of “Sell”.

Liminatus Pharma Trading Down 3.4%

Shares of Liminatus Pharma stock traded down $0.01 during midday trading on Friday, hitting $0.23. The company had a trading volume of 1,595,522 shares, compared to its average volume of 4,588,654. Liminatus Pharma has a 1-year low of $0.21 and a 1-year high of $33.66. The business’s 50 day simple moving average is $0.61 and its two-hundred day simple moving average is $1.10.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.